Anthracycline-induced cardiotoxicity in children with malignancies

Pediatrics International

Volumn 39, Issue 2, 1997, Pages 188-193

  Godoy, Lilian Ys ^a   Fukushige, Junichiro ^a   Igarashi, Hisaji ^a   Matsuzaki, Akinobu ^a   Ueda, Kohji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Anthracycline; Cardiotoxicity; Echocardiography

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CONGESTIVE HEART FAILURE; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FUNCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DISEASES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE;

EID: 0030895875     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1997.tb03579.x     Document Type: Article

References (17)

1. Blum RH, Carter SK. Adriamycin: A new anti-cancer drug with significant clinical activity. Ann. Intern. Med. 1974; 80: 249–59.
2. Von Hoff DD, Rozencweig M., Piccart M. The cardiotoxicity of anticancer agents. Semin. Oncol. 1982; 9: 23–33.
3. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy: Risk factors. Cancer 1977; 39: 1397–402.
4. Lefrac EA, Pitha J., Rosenhein S., Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1977; 39: 1397–402.
5. Rosenthal DS, Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Braunwald E. (ed.) Heart Disease: A Textbook of Cardiovascular Medicine. WB Saunders, Philadelphia. 1992; 1757.
6. Sahn DJ, De Maria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation 1978; 58: 1072.
7. Von Hoff DD, Layard MW, Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979; 91: 710–17.
8. Von Hoff DD, Rozencweig M., Layard M., Slavic M., Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am. J. Med. 1977; 62: 200–8.
9. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991; 324: 808–15.
10. Isner JM, Ferrans VJ, Cohen SR et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Am. J. Cardiol. 1983; 51: 1167–74.
11. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer. Treat. Rep. 1978; 62: 865–72.
12. Mosijczuk AD, Maj F., Ruymam FB, Mease AD, Bernier RD. Anthracycline cardiomyopathy in children: Report of two cases. Cancer 1979; 44: 1582–7.
13. Ali MK, Ewer MS, Gibbs HR, Swafford J., Graff K. Late Doxorubicin-associated cardiotoxicity in children. Cancer 1994; 74: 182–8.
14. Steinherz LJ, Steinherz PG, Tan CTR, Heller G., Murphy ML. Cardiac toxicity 4 to 20 years after completing Anthracycline therapy. JAMA 1991; 266: 1672–7.
15. Pihkala J., Sariola H., Saarinen U. Myocardial function and postmortem myocardial histology in children given Anthracycline therapy for cancer. Pediatr. Hematol. Oncol. 1994; 11: 259–69.
16. Steinherz LJ, Graham T., Hurwitz R. et al. Guidelines for cardiac monitoring of children during and after Anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942–9.
17. Jakacki RI, Larsen RL, Barber G., Heyman S., Fridman M., Silber JH. Comparison of cardiac function tests after anthracycline therapy in children. Cancer 1993; 72: 2739–45.